Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm

Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm

Abstract Background Carbapenem-resistant Pseudomonas aeruginosa (CRPA) represents an escalating healthcare hazard with high mortality worldwide, especially in presence of biofilm. The current study aimed to evaluate the anti-biofilm potentials of ceftazidime, colistin, gentamicin, and meropenem alon...

Full description

Bibliographic Details
Main Authors:	Mona Shaban E. M. Badawy, Walid F. Elkhatib, Rania I. Shebl
Format:	Article
Language:	English
Published:	BMC 2023-07-01
Series:	Annals of Clinical Microbiology and Antimicrobials
Subjects:	Pharmacodynamic Pseudomonas aeruginosa Ceftazidime Colistin Meropenem Gentamicin
Online Access:	https://doi.org/10.1186/s12941-023-00597-9

Similar Items

In Vitro Synergistic Activity of Antimicrobial Combinations against Carbapenem- and Colistin-Resistant <i>Acinetobacter baumannii</i> and <i>Klebsiella pneumoniae</i>
by: Paraskevi Mantzana, et al.
Published: (2023-01-01)

Cost-effectiveness analysis of ceftazidime avibactam versus colistin in carbapenem-resistant enterobacteriaceae in Iran
by: Zahra Goudarzi, et al.
Published: (2023-07-01)

Effectiveness of ceftazidime–avibactam versus colistin in treating carbapenem-resistant Enterobacteriaceae bacteremia
by: Hakeam A. Hakeam, et al.
Published: (2021-08-01)

Clinical Outcomes and Safety of Meropenem–Colistin versus Meropenem–Tigecycline in Patients with Carbapenem-Resistant <i>Acinetobacter baumannii</i> Pneumonia
by: Jae-Min Park, et al.
Published: (2021-07-01)

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam
by: Eric Wenzler, et al.
Published: (2020-10-01)

Ceftazidime-Avibactam versus Colistin for the Treatment of Infections Due to Carbapenem-Resistant Enterobacterales: A Multicenter Cohort Study
by: Almangour TA, et al.
Published: (2022-01-01)

Higher Brain Uptake of Gentamicin and Ceftazidime under Isoflurane Anesthesia Compared to Ketamine/Xylazine
by: Yeseul Ahn, et al.
Published: (2024-01-01)

Effect of Colistin, Fosfomycin and Meropenem/Vaborbactam on Carbapenem-Resistant Enterobacterales in Egypt: A Cross-Sectional Study
by: Shrief R, et al.
Published: (2022-10-01)

The effectiveness and nephrotoxicity of loading dose colistin combined with or without meropenem for the treatment of carbapenem-resistant A. baumannii
by: Wasan Katip, et al.
Published: (2020-08-01)

Review of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem-Vaborbactam and Imipenem-Relebactam in Carbapenemase Producing Klebsiella pneumoniae Isolates
by: Özlem AYDEMİR, et al.
Published: (2023-09-01)

The effectiveness of colistin/levofloxacin compared to colistin/meropenem in the treatment of ventilator-associated pneumonia (VAP) caused by carbapenem-resistant Acinetobacter baumannii: a randomized controlled clinical trial
by: Mahnaz Momenzadeh, et al.
Published: (2023-01-01)

Effectiveness and Nephrotoxicity of Loading Dose Colistin–Meropenem versus Loading Dose Colistin–Imipenem in the Treatment of Carbapenem-Resistant <i>Acinetobacter baumannii</i> Infection
by: Wasan Katip, et al.
Published: (2022-06-01)

Ceftazidime/avibactam combined with colistin: a novel attempt to treat carbapenem-resistant Gram-negative bacilli infection
by: Zihao Zheng, et al.
Published: (2023-10-01)

Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections
by: Helio S. Sader, et al.
Published: (2021-12-01)

The Role of Colistin in the Era of New β-Lactam/β-Lactamase Inhibitor Combinations
by: Abdullah Tarık Aslan, et al.
Published: (2022-02-01)

The combination effect of meropenem/sulbactam/polymyxin-B on the pharmacodynamic parameters for mutant selection windows against carbapenem-resistant Acinetobacter baumannii
by: Jiayuan Zhang, et al.
Published: (2022-11-01)

Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients
by: Sonia Luque, et al.
Published: (2021-06-01)

Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem in CKD and hemodialysis individuals
by: Guoliang Deng, et al.
Published: (2023-03-01)

Developmental Population Pharmacokinetics-Pharmacodynamics of Meropenem in Chinese Neonates and Young Infants: Dosing Recommendations for Late-Onset Sepsis
by: Yue-E Wu, et al.
Published: (2022-12-01)

Pharmacokinetics and Pharmacodynamics of Colistin Methanesulfonate in Healthy Chinese Subjects after Multi-Dose Regimen
by: Yaxin Fan, et al.
Published: (2022-06-01)

Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: Analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations
by: A. Oliva, et al.
Published: (2023-06-01)

In vitro Synergistic Activity of Ceftazidime-Avibactam in Combination with Aztreonam or Meropenem Against Clinical Enterobacterales Producing blaKPC or blaNDM
by: Kuai J, et al.
Published: (2023-05-01)

A Randomized Controlled Trial: Colistin Alone or Colistin and Meropenem: Which Is More Effective for the Management of Urinary Tract Infections?
by: Davood Yadegarynia, et al.
Published: (2022-12-01)

The Efficacy of Colistin Combined with Amikacin or Levofloxacin against Pseudomonas aeruginosa Biofilm Infection
by: Yuhang Wang, et al.
Published: (2022-10-01)

Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock: A Prospective Randomized Pilot Study
by: Hui-Ying Zhao, et al.
Published: (2017-01-01)

A Comparison of Colistin versus Colistin Plus Meropenem for the Treatment of Carbapenem-Resistant <i>Acinetobacter baumannii</i> in Critically Ill Patients: A Propensity Score-Matched Analysis
by: Wasan Katip, et al.
Published: (2020-09-01)

Colistin Monotherapy versus Colistin plus Meropenem Combination Therapy for the Treatment of Multidrug-Resistant <i>Acinetobacter baumannii</i> Infection: A Meta-Analysis
by: Chienhsiu Huang, et al.
Published: (2022-06-01)

Effects of Meropenem on Patients with Ventilator-Induced Pneumonia in Intensive Care Unit
by: Taraneh Naghibi, et al.
Published: (2022-11-01)

A pharmacodynamic strategy to optimize empirical antibiotic therapy for gram-negative bacteria in a Brazilian Intensive Care Unit
by: Carlos R.V. Kiffer, et al.

Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates
by: María M. Montero, et al.
Published: (2021-09-01)

Relationship between adverse drug reactions to antibacterial agents and the Klebsiella pneumoniae carbapenemase-producing (KPC) Klebsiella pneumoniae outbreak: insight from a pharmacovigilance study
by: Milo Gatti, et al.
Published: (2019-11-01)

Population Pharmacokinetics and Probability of Target Attainment of Different Dosing Regimens of Ceftazidime in Critically Ill Patients with a Proven or Suspected <i>Pseudomonas aeruginosa</i> Infection
by: Annabel Werumeus Buning, et al.
Published: (2021-05-01)

In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula
by: Ágnes Sonnevend, et al.
Published: (2020-10-01)

Cost-effectiveness of ceftazidime/avibactam plus metronidazole versus meropenem as first-line empiric therapy for the treatment of complicated intra-abdominal infections: A study based on the in-vitro surveillance data in China
by: Xiaoping Shi, et al.
Published: (2023-03-01)

Meropenem Administered via Intravenous Regional Limb Perfusion for Orthopedic Sepsis in Horses: A Clinical Retrospective Study
by: Allison P. Mosichuk, et al.
Published: (2021-03-01)

Proteomic analysis of ceftazidime and meropenem-exposed Pseudomonas aeruginosa ATCC 9027
by: Hong Loan Ngo, et al.
Published: (2023-09-01)

Evaluating Mono- and Combination Therapy of Meropenem and Amikacin against Pseudomonas aeruginosa Bacteremia in the Hollow-Fiber Infection Model
by: Minyon L. Avent, et al.
Published: (2022-06-01)

Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion
by: Andrea Marino, et al.
Published: (2023-10-01)

mcr-1 and blaKPC-3 in Escherichia coli Sequence Type 744 after Meropenem and Colistin Therapy, Portugal
by: Marta Tacão, et al.
Published: (2017-08-01)

Adverse Drug Reactions Relevant to Drug Resistance and Ineffectiveness Associated with Meropenem, Linezolid, and Colistin: An Analysis Based on Spontaneous Reports from the European Pharmacovigilance Database
by: Bogdan Ioan Vintila, et al.
Published: (2023-05-01)